GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Cyclically Adjusted PB Ratio

Illumina (Illumina) Cyclically Adjusted PB Ratio : 3.48 (As of May. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Cyclically Adjusted PB Ratio?

As of today (2024-05-15), Illumina's current share price is $115.01. Illumina's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $33.09. Illumina's Cyclically Adjusted PB Ratio for today is 3.48.

The historical rank and industry rank for Illumina's Cyclically Adjusted PB Ratio or its related term are showing as below:

ILMN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.93   Med: 19.32   Max: 31.26
Current: 3.49

During the past years, Illumina's highest Cyclically Adjusted PB Ratio was 31.26. The lowest was 2.93. And the median was 19.32.

ILMN's Cyclically Adjusted PB Ratio is ranked worse than
71.43% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.02 vs ILMN: 3.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Illumina's adjusted book value per share data for the three months ended in Mar. 2024 was $36.063. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $33.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Illumina's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted PB Ratio Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.33 20.63 16.31 6.94 4.27

Illumina Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.67 5.98 4.27 4.27 4.15

Competitive Comparison of Illumina's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted PB Ratio falls into.



Illumina Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Illumina's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=115.01/33.09
=3.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Illumina's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=36.063/129.4194*129.4194
=36.063

Current CPI (Mar. 2024) = 129.4194.

Illumina Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.751 100.560 9.975
201409 8.974 100.428 11.565
201412 10.185 99.070 13.305
201503 11.270 99.621 14.641
201506 12.397 100.684 15.935
201509 13.228 100.392 17.053
201512 12.611 99.792 16.355
201603 13.538 100.470 17.439
201606 14.023 101.688 17.847
201609 15.249 101.861 19.375
201612 15.028 101.863 19.093
201703 17.472 102.862 21.983
201706 18.596 103.349 23.287
201709 19.555 104.136 24.303
201712 18.701 104.011 23.269
201803 20.498 105.290 25.196
201806 22.156 106.317 26.970
201809 23.830 106.507 28.957
201812 25.565 105.998 31.214
201903 27.109 107.251 32.712
201906 29.270 108.070 35.052
201909 30.197 108.329 36.076
201912 31.381 108.420 37.459
202003 31.571 108.902 37.519
202006 31.253 108.767 37.187
202009 32.192 109.815 37.939
202012 32.151 109.897 37.862
202103 33.716 111.754 39.045
202106 35.238 114.631 39.784
202109 67.471 115.734 75.449
202112 68.408 117.630 75.264
202203 69.356 121.301 73.998
202206 66.522 125.017 68.865
202209 42.873 125.227 44.308
202212 41.766 125.222 43.166
202303 42.361 127.348 43.050
202306 41.487 128.729 41.710
202309 37.141 129.860 37.015
202312 36.132 129.419 36.132
202403 36.063 129.419 36.063

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (NAS:ILMN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Illumina Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (Illumina) Business Description

Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Executives
Aimee L Hoyt officer: SVP, Chief People Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen director, officer: Chief Executive Officer 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi officer: SVP Product Development 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno director C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen officer: VP, Chief Accounting Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell officer: Sr VP & General Counsel 5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank officer: Chief Public Affairs Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo officer: SVP Chief Medical Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins officer: SVP, Chief Information Officer 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels officer: Chief of Global Operations 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley officer: President & CEO 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121

Illumina (Illumina) Headlines

From GuruFocus

Q2 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc Acquires Grail Inc Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Illumina Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Illumina Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024